The global one-step ELISA market size is anticipated to reach US$ 9.4 Billion in 2032 and exhibit steady growth at a CAGR of 3.8% in the forecast period from 2022 to 2032. Increasing research activities in the field of biomarkers are projected to drive the one-step ELISA market in future. According to FMI, sales in one-step ELISA are likely to be valued at US$ 6.3 Billion in 2022.
| Report Attribute | Details |
| One-step ELISA Market Estimated Base Year Value (2021) | US$ 5.1 Billion |
| One-step ELISA Market Expected Market Value (2022) | US$ 6.3 Billion |
| One-step ELISA Market Anticipated Forecast Value (2032) | US$ 9.4 Billion |
| One-step ELISA Market Projected Growth Rate (2022-2032) | 3.8% CAGR |
Enzyme-Linked Immunosorbent Assay, commonly known as ELISA, is considered to be one of the gold standards for in-vitro diagnostic testing. Despite the ongoing development of point of care, microfluidics, immunosensors, and lab-on-chip technologies, ELISA is currently showcasing high demand.
The increasing prevalence of various infectious and chronic diseases worldwide is anticipated to push the demand for one-step ELISA in the upcoming years. The high demand for relatively low cost diagnostic tools in emerging economies is also expected to drive the market.
ELISA has high throughput and unmatched reliability for the management and monitoring of disease markers. In conventional assays, microplates are usually coated with antibodies that bind to the selected target proteins.
Antibodies that bind to a different site on the target protein are utilized for the detection of bound proteins. But, the modern one-step ELISA has simplified this process.
This type of test is performed with the help of a semi-homogeneous mixture wherein the sandwich complex is formed in one step. It is then anchored to the plate for identification with immunoaffinity tags.
The rising prevalence of HIV/AIDS across the globe is anticipated to boost the one-step ELISA market growth in the assessment period. As per the World Health Organization (WHO), in 2020, approximately 37.7 million people were living with HIV/AIDS globally, while 680,000 people had died of HIV-related illnesses the same year. These numbers are estimated to surge in future years, thereby augmenting the market.
In addition to that, the sudden outbreak of the COVID-19 pandemic in December 2019 led to the increasing usage of ELISA for the rapid detection of coronavirus. The massive approvals, valuations, and research activities associated with multiple immunoassay analyzers and consumables backed by the rising cases of COVID-19 is also likely to accelerate the market.
Government bodies of various countries across the globe are expected to put forward stringent norms for the commercialization and approval of immunoassay instruments and consumables.
Numerous technological challenges posed by the immunoassay kits and reagents, including false negatives, low detection limits of the available antibodies, and cross-reactivity of antibodies are also expected to hamper the one-step ELISA market size in the evaluation period.
Based on region, North America is expected to account for the largest one-step ELISA market share in the forthcoming years. The rising geriatric population in the U.S. and Canada and increasing investments in the development of their healthcare infrastructure are anticipated to propel the regional market.
According to the U.S. Department of Health and Human Services, the population belonging to the age group of 65 years and above was 54.1 million in 2019 in this country, including 24.1 million men and 30 million women. This trend is set to continue throughout the forthcoming years, thereby propelling the North America market.
Sales of one-step ELISA are anticipated to surge in Asia Pacific on the back of presence of various prominent market participants in India and China. In October 2020, Cipla Limited, for instance, commercialized its new antibody detection kits by joining hands with KARWA Ltd. in India for COVID-19. Thus, the development and commercialization of multiple products by key companies in this region is set to drive the market.
The high demand for pregnancy tests in Asia Pacific owing to the urgent need for early diagnosis is another major factor that is anticipated to propel the market. As per UNICEF, India accounts for nearly one fifth of the annual child births in the world with the birth of 25 million children every year. It is expected to grow in future, thereby fostering growth.
The global one-step ELISA market contains a large number of key players. Some of them are AnaSpec, Inc., Abcam plc, InBios International, Inc., Boster Biological Technology, PerkinElmer, Inc., DIALAB GmbH, and IDS PLC among others.
Majority of the leading players are engaging in joint ventures, collaborations, and mergers and acquisitions to gain a competitive edge in the market. A few other key players are aiming to develop innovative products to expand their product portfolios and generate high shares in the market.
Meanwhile, some of the large-scale enterprises are expanding their distribution channels and production capacities to cater to the surging consumer demand.
| Report Attribute | Details |
| Growth Rate | CAGR of 3.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Target:
By Sample Type:
By End User:
By Region:
The global one-step ELISA market is anticipated to reach US$ 9.4 Billion in 2032.
North America is set to lead the one-step ELISA market in the forecast period.
AnaSpec, Inc., Abcam plc, InBios International, Inc., Boster Biological Technology, PerkinElmer, Inc., DIALAB GmbH, and IDS PLC are some of the renowned companies in the one-step ELISA market.
Explore Similar Insights
One-step ELISA Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
